共 25 条
[21]
Cross A.H., Goorha R.M., Nuss R., Behm F.G., Murphy S.B., Kalwinsky D.K., Raimondi S., Kitchingman G.R., Mirro J., Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity, Blood, 72, pp. 579-587, (1988)
[22]
Gucalp R., Paietta E., Weinberg V., Papenhausen P., Dutcher J.P., Wiernick P.H., Terminal transferase expression in acute myeloid leukemia: biology and prognosis, Br. J. Haematol., 77, pp. 48-54, (1991)
[23]
Willman C.L., Kopecky K.J., Appelbaum F., Grever M.R., Head D.R., Elias L., Balcerzak S.P., Mills G.M., Hynes H.E., Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression is associated with a decreased complete remission (CR) rate and CD34-positive patients more frequently achieve CR with high-dose cytosine arabinoside, Proceedings of the American Society of Clinical Oncology, 11, (1992)
[24]
Drexler G.H., Thiel E., Ludwig W.D., Acute myeloid leukemias expressing lymphoid-associated antigens: Diagnostic incidence and prognostic significance, Leukemia, 7, pp. 489-498, (1993)
[25]
Ball E.D., Davis E.B., Griffin J.D., Mayer R.J., Davey F.R., Arthuer D.C., Wunster-Hill D., Noll W., Tarek-Elghetany M., Allen S.L., Rai K., Lee E.J., Schiffer L.A., Bloomfield C.D., Prognostic value of lymphocyte surface markers in acute myeloid leukemia, Blood, 77, pp. 2242-2250, (1991)